COMMUNIQUÉS West-GlobeNewswire

Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells
16/10/2026
New Preclinical Findings Identify Potential Strategy to Remodel Resistant Tumor State & Restore Therapeutic Vulnerability MELBOURNE, Australia, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB [...]
Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology
16/10/2026
DOYLESTOWN, Pa., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of [...]
Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children
16/10/2026
Final European Commission decision expected during Q4 2026 COPENHAGEN, Denmark, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Medicinal Products for Human [...]
Biomerica Reports First Quarter Fiscal 2027 Financial Results
16/10/2026
InFoods® IBS Commercial Progress: Medicare-related test orders increased 120% in September 2026 compared to August, with growing physician participation and repeat ordering activity InFoods® IBS update: 100% of all [...]
Quantum-Si to Provide a Business Update and Report Third Quarter 2026 Financial Results on November 5, 2026
16/10/2026
BRANFORD, Conn., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule [...]
hear.com Receives 2026 Global Recognition Award for Hearing Care Innovation
16/10/2026
Recognition honors hear.com’s Clinic-in-a-Box® teleaudiology platform and Horizon IX hearing aids for expanding access to personalized, medical-grade hearing care MIAMI, Oct. 16, 2026 (GLOBE NEWSWIRE) -- hear.com, an [...]
Nanox AI Ltd. Enters into Distribution Agreement with Technologic s.r.l., an Affiliate of Tecnologie Avanzate, to Commercialize Nanox.AI Bone Solution in Italy
16/10/2026
Agreement aims to expand the commercial reach of Nanox.AI's Bone Solution in the Italian healthcare market. Collaboration leverages Tecnologie Avanzate's 50 years of experience in the Italian medical technology market, [...]
twiist™ Automated Insulin Delivery System is Now Cleared for Adults with Type 2 Diabetes
16/10/2026
Clearance expands twiist's precise insulin delivery and personalized automation to the largest population of people treated with insulin, with time-in-range improvements seen in as little as one day in a pivotal trial 1 [...]
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
16/10/2026
PALO ALTO, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today [...]
OXB Appoints Joachim Kreuzburg as Independent Non-Executive Director
16/10/2026
OXB Appoints Joachim Kreuzburg as Independent Non-Executive Director Oxford, UK – 16 October 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces the appointment of Dr [...]
Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026
16/10/2026
Company to host PDAC focused investor webcast on Friday, October 23, 2026, 7:30 am ET BOSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed [...]
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types
16/10/2026
Positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after first 12 weeks of treatment Optional reduction of infusion time for 350 mg dose to 15 to 30 minutes, after a [...]
Fractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation
16/10/2026
REMAIN-1 met its six-month co-primary endpoint with high statistical significance (p=0.0023; mITT population); demonstrated 80% retention of GLP-1 induced weight loss vs 67% for sham 32% of Revita ® participants in [...]
Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis
16/10/2026
Former Dermavant Chief Scientific Officer led development of tapinarof, the first FDA-approved AhR agonist, from mechanistic understanding through approval and commercialization Will lead AT177 through IND-enabling [...]
Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease
16/10/2026
BOSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
Semax Peptide Introduced by Kylo Peptides for Laboratory Use
16/10/2026
Sheridan, Wyoming, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides has added Semax [ https://kylopeptides.com/product/semax/ ] to its research catalog this week. The compound is a synthetic peptide supplied only for [...]
CHMP recommends approval of Johnson & Johnson’s TALVEY®▼ (talquetamab) plus daratumumab in earlier line treatment of relapsed/refractory multiple myeloma
16/10/2026
If approved, TALVEY ® plus daratumumab will be the only GPRC5D-targeting bispecific antibody combination therapy for relapsed or refractory multiple myeloma as early as second line CHMP recommendation based on Phase 3 [...]
Senturi Pharma announces exclusive European distribution agreement for PERTZYE®
16/10/2026
STOCKHOLM, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Senturi Pharma AB and Digestive Care, Inc. today announced the signing of an exclusive distribution agreement concerning PERTZYE ® (pancrelipase) in Europe. Under the [...]
Three Orelabrutinib Studies Presented in Oral Sessions at the 88th Annual Meeting of the Japanese Society of Hematology
16/10/2026
BEIJING, Oct. 16, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that three studies [...]

Pages